$LUMO
Lumos Pharma Inc Stock $lumo

$lumo Overview Financials Valuation SEC Filings Company Website

2013 Q2 Form 10-Q Financial Statement

#000112623413000069 Filed on May 08, 2013

Income Statement

Concept	2013 Q2	2013 Q1	2012 Q1
Revenue	$232.0K	$302.0K	$471.0K
YoY Change	-60.68%	-35.88%	-22.02%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.300M	$2.000M	$1.500M
YoY Change	4.55%	33.33%	15.38%
% of Gross Profit
Research & Development	$5.037M	$6.343M	$3.830M
YoY Change	6.27%	65.61%	20.44%
% of Gross Profit
Depreciation & Amortization	$200.0K	$200.0K	$175.0K
YoY Change	0.0%	14.29%	0.57%
% of Gross Profit
Operating Expenses	$7.301M	$8.344M	$5.288M
YoY Change	5.95%	57.79%	17.62%
Operating Profit	-$7.069M	-$8.042M	-$4.817M
YoY Change	12.19%	66.95%	23.77%
Interest Expense	$0.00	$0.00	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$8.000K	$108.0K	-$25.00K
YoY Change	0.0%	-532.0%	316.67%
Pretax Income	-$7.077M	-$7.934M	-$4.800M
YoY Change	12.33%	65.29%	23.08%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$7.077M	-$7.934M	-$4.842M
YoY Change	12.17%	63.86%	24.25%
Net Earnings / Revenue	-3050.43%	-2627.15%	-1028.03%
Basic Earnings Per Share	-$0.28	-$0.33	-$0.23
Diluted Earnings Per Share	-$0.28	-$0.33	-$2.087M
COMMON SHARES
Basic Shares Outstanding	25.60M shares	25.60M shares	20.61M shares
Diluted Shares Outstanding		23.86M shares	20.61M shares

Balance Sheet

Concept	2013 Q2	2013 Q1	2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$59.30M	$64.00M	$35.80M
YoY Change	90.68%	78.77%
Cash & Equivalents	$59.04M	$63.28M	$33.27M
Short-Term Investments	$200.0K	$700.0K	$2.500M
Other Short-Term Assets	$500.0K	$700.0K	$300.0K
YoY Change	66.67%	133.33%
Inventory
Prepaid Expenses	$535.0K	$657.0K	$292.0K
Receivables
Other Receivables
Total Short-Term Assets	$61.07M	$65.77M	$37.22M
YoY Change	85.79%	76.7%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.942M	$5.889M	$6.229M
YoY Change	-5.16%	-5.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$5.942M	$5.889M	$6.229M
YoY Change	-5.16%	-5.46%
TOTAL ASSETS
Total Short-Term Assets	$61.07M	$65.77M	$37.22M
Total Long-Term Assets	$5.942M	$5.889M	$6.229M
Total Assets	$67.01M	$71.66M	$43.45M
YoY Change	71.23%	64.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.076M	$865.0K	$803.0K
YoY Change	87.13%	7.72%
Accrued Expenses	$2.817M	$2.015M	$1.226M
YoY Change	59.51%	64.36%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$186.0K	$177.0K	$93.00K
YoY Change	93.75%	90.32%
Total Short-Term Liabilities	$4.163M	$3.141M	$2.310M
YoY Change	59.14%	35.97%
LONG-TERM LIABILITIES
Long-Term Debt	$1.129M	$1.136M	$6.900M
YoY Change	-83.64%	-83.54%
Other Long-Term Liabilities	$7.400M	$7.400M	$1.500M
YoY Change	428.57%	393.33%
Total Long-Term Liabilities	$8.492M	$8.520M	$8.339M
YoY Change	2.46%	2.17%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.163M	$3.141M	$2.310M
Total Long-Term Liabilities	$8.492M	$8.520M	$8.339M
Total Liabilities	$12.66M	$11.66M	$10.65M
YoY Change	16.06%	9.5%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock			$207.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$54.40M	$60.00M	$32.80M
YoY Change
Total Liabilities & Shareholders Equity	$67.01M	$71.66M	$43.45M
YoY Change	71.23%	64.93%

Cashflow Statement

Concept	2013 Q2	2013 Q1	2012 Q1
OPERATING ACTIVITIES
Net Income	-$7.077M	-$7.934M	-$4.842M
YoY Change	12.17%	63.86%	24.25%
Depreciation, Depletion And Amortization	$200.0K	$200.0K	$175.0K
YoY Change	0.0%	14.29%	0.57%
Cash From Operating Activities	-$4.900M	-$6.600M	-$5.640M
YoY Change	2.08%	17.02%	30.07%
INVESTING ACTIVITIES
Capital Expenditures	-$200.0K	$62.00K	$709.0K
YoY Change	-50.0%	-91.26%	1377.08%
Acquisitions		$0.00	$0.00
YoY Change
Other Investing Activities	$500.0K	$700.0K	$100.0K
YoY Change	-70.59%	600.0%	-66.67%
Cash From Investing Activities	$300.0K	$685.0K	-$659.0K
YoY Change	-78.57%	-203.95%	-398.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		-$49.04M	-$131.0K
YoY Change		37331.3%
Debt Paid & Issued, Net		$37.00K	$23.00K
YoY Change		60.87%	0.0%
Cash From Financing Activities	300.0K	$48.97M	$78.00K
YoY Change	-40.0%	62676.92%	-290.24%
NET CHANGE
Cash From Operating Activities	-4.900M	-6.600M	-$5.640M
Cash From Investing Activities	300.0K	$685.0K	-$659.0K
Cash From Financing Activities	300.0K	$48.97M	$78.00K
Net Change In Cash	-4.300M	$49.65M	-$6.221M
YoY Change	48.28%	-898.12%	49.69%
FREE CASH FLOW
Cash From Operating Activities	-$4.900M	-$6.600M	-$5.640M
Capital Expenditures	-$200.0K	$62.00K	$709.0K
Free Cash Flow	-$4.700M	-$6.662M	-$6.349M
YoY Change	6.82%	4.93%	44.82%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1300000	USD
CY2013Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	8520000	USD
CY2012Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	8583000	USD
CY2013Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	457000	USD
CY2012Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	196000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	972000	USD
CY2013Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	865000	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1659000	USD
CY2013Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2015000	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2978000	USD
CY2013Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3190000	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	122514000	USD
CY2013Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	172469000	USD
CY2013Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	966000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9500000	USD
CY2012Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	736000	USD
CY2012Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4000000	shares
CY2013Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4400000	shares
CY2012Q4	us-gaap	Assets Assets	29429000	USD
CY2013Q1	us-gaap	Assets Assets	71655000	USD
CY2013Q1	us-gaap	Assets Current AssetsCurrent	65766000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	23389000	USD
CY2012Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	173000	USD
CY2013Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	9000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	9000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63278000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20250000	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33269000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39490000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	63278000	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-6221000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	43028000	USD
CY2013Q1	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	747000	USD
CY2012Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	1494000	USD
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	38833334	shares
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	38833334	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20985192	shares
CY2013Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25604839	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20985192	shares
CY2013Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25604839	shares
CY2013Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	256000	USD
CY2012Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	210000	USD
CY2013Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, and certificates of deposit. Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits. At times, the Company’s cash and cash equivalents balance exceeds the federally insured limits. To limit the credit risk, the Company invests its excess cash primarily in high quality securities such as money market funds.</font></div></div>
CY2013Q1	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	0	USD
	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	-449000	USD
CY2012Q1	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	0	USD
CY2013Q1	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	84000	USD
CY2012Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	84000	USD
CY2012Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1405000	USD
CY2013Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1384000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	23100000	USD
CY2013Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	25900000	USD
CY2013Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	212000	USD
CY2012Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	175000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3961000	USD
CY2012Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	104797000	USD
CY2013Q1	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	112731000	USD
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.33
CY2012Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23
CY2013Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	8600000	USD
CY2012Q1	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
CY2013Q1	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	542000	USD
CY2013Q1	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	0	USD
CY2012Q1	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	0	USD
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-12535000	USD
CY2013Q1	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-747000	USD
CY2012Q1	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	0	USD
CY2012Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	20000	USD
CY2013Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	38000	USD
CY2012Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1458000	USD
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2001000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	38944000	USD
CY2012Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2013Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2012Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1042000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-366000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-106000	USD
CY2012Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-35000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3483000	USD
CY2013Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	335000	USD
	us-gaap	Increase Decrease In Notes Receivable Related Parties IncreaseDecreaseInNotesReceivableRelatedParties	350000	USD
CY2012Q1	us-gaap	Increase Decrease In Notes Receivable Related Parties IncreaseDecreaseInNotesReceivableRelatedParties	0	USD
CY2013Q1	us-gaap	Increase Decrease In Notes Receivable Related Parties IncreaseDecreaseInNotesReceivableRelatedParties	0	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-457000	USD
CY2013Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-261000	USD
CY2012Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-724000	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	250000	USD
CY2012Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	117000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-657000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	189000	USD
CY2012Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	8000	USD
CY2013Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	8000	USD
	us-gaap	Interest Paid InterestPaid	150000	USD
CY2013Q1	us-gaap	Interest Paid InterestPaid	8000	USD
CY2012Q1	us-gaap	Interest Paid InterestPaid	10000	USD
CY2013Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	2000	USD
CY2012Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	4000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1769000	USD
CY2012Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	5085000	USD
CY2013Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	5093000	USD
CY2013Q1	us-gaap	Liabilities Liabilities	11661000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	11502000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	29429000	USD
CY2013Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	71655000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2919000	USD
CY2013Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3141000	USD
CY2012Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1400000	USD
CY2013Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	177000	USD
CY2012Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	204000	USD
CY2013Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1136000	USD
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1178000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	48966000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	169458000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	78000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9321000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-659000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	685000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-96859000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-5640000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6623000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-7934000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-112691000	USD
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	-4842000	USD
CY2013Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2012Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-583000	USD
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-7934000	USD
CY2012Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4842000	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	8344000	USD
	us-gaap	Operating Expenses OperatingExpenses	123443000	USD
CY2012Q1	us-gaap	Operating Expenses OperatingExpenses	5288000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-115737000	USD
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4817000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8042000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	434000	USD
CY2012Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	-21000	USD
CY2013Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	114000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2463000	USD
CY2012Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-25000	USD
CY2013Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	108000	USD
CY2013Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2012Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	4000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	505000	USD
CY2013Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
CY2013Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2012Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	120000	USD
CY2012Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	13282000	USD
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	62000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8154000	USD
CY2012Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	709000	USD
	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	113000	USD
CY2012Q1	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	0	USD
CY2013Q1	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	0	USD
CY2013Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0.00	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0.00	shares
CY2013Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2013Q1	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2012Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	907000	USD
CY2013Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	657000	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	49035000	USD
CY2012Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	135000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	91480000	USD
CY2012Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	67743000	USD
CY2012Q1	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	USD
CY2013Q1	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	USD
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	3479000	USD
CY2012Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	8215000	USD
CY2013Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2013Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2012Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	50000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	50000	USD
CY2012Q1	us-gaap	Profit Loss ProfitLoss	-4842000	USD
	us-gaap	Profit Loss ProfitLoss	-113274000	USD
CY2013Q1	us-gaap	Profit Loss ProfitLoss	-7934000	USD
CY2013Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	656000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	636000	USD
CY2013Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5889000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6040000	USD
CY2013Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	32000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	441000	USD
CY2012Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	30000	USD
CY2013Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	37000	USD
CY2012Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	23000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	513000	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6343000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	84499000	USD
CY2012Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3830000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	1629000	USD
CY2013Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2012Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2013Q1	us-gaap	Revenue From Grants RevenueFromGrants	302000	USD
CY2012Q1	us-gaap	Revenue From Grants RevenueFromGrants	471000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	7706000	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	966000	USD
CY2012Q1	us-gaap	Share Based Compensation ShareBasedCompensation	736000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	9510000	USD
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	11.68
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	955000	USD
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2792067	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.53
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	114000	USD
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	4500	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	701750	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.52
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	30100000	USD
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3752413	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4430016	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.34
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.51
CY2013Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.07
CY2013Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.00
CY2013Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11.81
CY2013Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	24400000	USD
	us-gaap	Stock Issued1 StockIssued1	1654000	USD
CY2013Q1	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2012Q1	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2013Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	4600000	shares
CY2013Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	19647	shares
CY2013Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	48916000	USD
CY2013Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	966000	USD
CY2013Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	119000	USD
CY2013Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	59994000	USD
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	17927000	USD
CY2013Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>
CY2013Q1	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2700000	USD
CY2012Q1	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	961000	USD
CY2012Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20613146	shares
CY2013Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23860469	shares
CY2012Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20613146	shares
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23860469	shares
CY2013Q1	nlnk	Cash And Cash Equivalents Excluding Certificates Of Deposit CashAndCashEquivalentsExcludingCertificatesOfDeposit	63278000	USD
CY2012Q4	nlnk	Cash And Cash Equivalents Excluding Certificates Of Deposit CashAndCashEquivalentsExcludingCertificatesOfDeposit	20250000	USD
CY2013Q1	nlnk	Design Build Agreement Story Construction Cost DesignBuildAgreementStoryConstructionCost	861000	USD
CY2013Q1	nlnk	Design Build Agreement Story Construction Square Feet DesignBuildAgreementStoryConstructionSquareFeet	11800
	nlnk	Increase Decrease In State Research And Development Credit Receivable IncreaseDecreaseInStateResearchAndDevelopmentCreditReceivable	-627000	USD
CY2013Q1	nlnk	Intrinsic Value Price Per Share Base IntrinsicValuePricePerShareBase	12.27
CY2013Q1	nlnk	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition In Years EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognitionInYears	3.1
	nlnk	Forgiveness Of Notes Receivable From Related Parties ForgivenessOfNotesReceivableFromRelatedParties	350000	USD
CY2012Q1	nlnk	Forgiveness Of Notes Receivable From Related Parties ForgivenessOfNotesReceivableFromRelatedParties	0	USD
CY2013Q1	nlnk	Forgiveness Of Notes Receivable From Related Parties ForgivenessOfNotesReceivableFromRelatedParties	0	USD
CY2012Q1	nlnk	Increase Decrease In State Research And Development Credit Receivable IncreaseDecreaseInStateResearchAndDevelopmentCreditReceivable	-45000	USD
CY2013Q1	nlnk	Increase Decrease In State Research And Development Credit Receivable IncreaseDecreaseInStateResearchAndDevelopmentCreditReceivable	-85000	USD
CY2013Q1	nlnk	Memorandum Of Agreement Isurp Grant Financing MemorandumOfAgreementIsurpGrantFinancing	1000000	USD
CY2013Q1	nlnk	Memorandum Of Agreement Isurp Increase In Rents MemorandumOfAgreementIsurpIncreaseInRents	70000	USD
CY2013Q1	nlnk	Intrinsic Value Unvested IntrinsicValueUnvested	5700000	USD
CY2012Q4	nlnk	Lab Equipment LabEquipment	3297000	USD
CY2013Q1	nlnk	Lab Equipment LabEquipment	3330000	USD
CY2013Q1	nlnk	Memorandum Of Agreement Isurp Square Feet MemorandumOfAgreementIsurpSquareFeet	11800
	nlnk	Noncash Issuance Of Common Stock Dividend To Preferred Shareholders NoncashIssuanceOfCommonStockDividendToPreferredShareholders	6000	USD
CY2012Q1	nlnk	Noncash Issuance Of Common Stock Dividend To Preferred Shareholders NoncashIssuanceOfCommonStockDividendToPreferredShareholders	0	USD
CY2013Q1	nlnk	Noncash Issuance Of Common Stock Dividend To Preferred Shareholders NoncashIssuanceOfCommonStockDividendToPreferredShareholders	0	USD
CY2013Q1	nlnk	Reduction Of Ipo Offering Costs ReductionOfIpoOfferingCosts	0	USD
CY2012Q1	nlnk	Reduction Of Ipo Offering Costs ReductionOfIpoOfferingCosts	0	USD
	nlnk	Reduction Of Ipo Offering Costs ReductionOfIpoOfferingCosts	158000	USD
CY2013Q1	nlnk	Royalty Obligation Payable Noncurrent RoyaltyObligationPayableNoncurrent	6000000	USD
CY2012Q4	nlnk	Royalty Obligation Payable Noncurrent RoyaltyObligationPayableNoncurrent	6000000	USD
CY2013Q1	nlnk	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Vesting Term In Years ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageVestingTermInYears	7.5
CY2013Q1	nlnk	Share Based Compensation Shares Authorized Under Stock Option Plans Exercisable Options Weighted Average Vesting Term In Years ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisableOptionsWeightedAverageVestingTermInYears	6.6
CY2012Q4	nlnk	State Research And Development Credit Receivable StateResearchAndDevelopmentCreditReceivable	542000	USD
CY2013Q1	nlnk	State Research And Development Credit Receivable StateResearchAndDevelopmentCreditReceivable	627000	USD
CY2012Q4	nlnk	Total Leasehold Improvements And Equipment TotalLeaseholdImprovementsAndEquipment	9018000	USD
CY2013Q1	nlnk	Total Leasehold Improvements And Equipment TotalLeaseholdImprovementsAndEquipment	9079000	USD
CY2013Q1	dei	Amendment Flag AmendmentFlag	false
CY2013Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2013Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2013Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013Q1	dei	Document Period End Date DocumentPeriodEndDate	2013-03-31
CY2013Q1	dei	Document Type DocumentType	10-Q
CY2013Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001126234
CY2013Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25604839	shares
CY2013Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2013Q1	dei	Entity Registrant Name EntityRegistrantName	NEWLINK GENETICS CORP
CY2013Q1	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2013Q1	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No

Files In Submission

Name	View Source	Status
0001126234-13-000069-index-headers.html	Edgar Link	pending
0001126234-13-000069-index.html	Edgar Link	pending
0001126234-13-000069.txt	Edgar Link	pending
0001126234-13-000069-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
isurplogo20130331.jpg	Edgar Link	pending
logo20130331.jpg	Edgar Link	pending
nlnk-20130331.xml	Edgar Link	completed
nlnk-20130331.xsd	Edgar Link	pending
nlnk-20130331x10q.htm	Edgar Link	pending
nlnk-20130331xex101.htm	Edgar Link	pending
nlnk-20130331xex311.htm	Edgar Link	pending
nlnk-20130331xex312.htm	Edgar Link	pending
nlnk-20130331xex321.htm	Edgar Link	pending
nlnk-20130331_cal.xml	Edgar Link	unprocessable
nlnk-20130331_def.xml	Edgar Link	unprocessable
nlnk-20130331_lab.xml	Edgar Link	unprocessable
nlnk-20130331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LUMO
Lumos Pharma Inc Stock $lumo

2013 Q2 Form 10-Q Financial Statement

#000112623413000069 Filed on May 08, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO Lumos Pharma Inc Stock $lumo

2013 Q2 Form 10-Q Financial Statement

#000112623413000069 Filed on May 08, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO
Lumos Pharma Inc Stock $lumo